2.65

3.11% 0.08

After Hours: 2.70 0.05 +1.89%

Black Diamond Therapeutics Inc (BDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Black Diamond Therapeutics Inc stock is traded at $2.65, with a volume of 392.06K. It is up +3.11% in the last 24 hours and down -7.34% over the past month. Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Previous Close:

$2.57

Open:

$2.6

24h Volume:

392.06K

Relative Volume:

0.34

Market Cap:

$149.95M

Revenue:

Net Income/Loss:

$-82.44M

P/E Ratio:

-1.1623

EPS:

-2.28

Net Cash Flow:

$-66.75M

1W Performance:

+4.33%

1M Performance:

-7.34%

6M Performance:

-44.21%

1Y Performance:

+22.12%

1-Day Range:

$2.59

$2.745

1-Week Range:

$2.41

$2.745

52-Week Range:

$2.19

$7.66

Black Diamond Therapeutics Inc Stock (BDTX) Company Profile

Name

Black Diamond Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

617-417-5868

Address

ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

BDTX's Discussions on Twitter

Compare BDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BDTX Black Diamond Therapeutics Inc	2.65	149.95M	0	-82.44M	-66.75M	-1.88
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-24	Initiated	Raymond James	Outperform
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold
Jan-07-21	Initiated	Wedbush	Outperform
Nov-24-20	Initiated	Berenberg	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	Canaccord Genuity	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	JP Morgan	Overweight
Feb-24-20	Initiated	Jefferies	Buy

View All

Black Diamond Therapeutics Inc Stock (BDTX) Latest News

Nov 29, 2024

Vestal Point Capital LP Grows Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - MarketBeat

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail

Nov 29, 2024

Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR

Nov 29, 2024

Nov 16, 2024

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Decrease in Short Interest - MarketBeat

Nov 16, 2024

Nov 14, 2024

T. Rowe Price Investment Management, Inc. Expands Stake in Black Diamond Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Vestal Point Capital, LP Increases Stake in Black Diamond Therap - GuruFocus.com

Nov 14, 2024

Nov 08, 2024

What is HC Wainwright's Estimate for BDTX FY2024 Earnings? - MarketBeat

Nov 08, 2024

Wedbush Has Optimistic View of BDTX FY2024 Earnings - MarketBeat

Nov 08, 2024

Nov 06, 2024

Black Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 06, 2024

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 06, 2024

Nov 05, 2024

Black Diamond Therapeutics Reports Promising Q3 2024 Results - TipRanks

Nov 05, 2024

Black Diamond: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 05, 2024

BDTXBlack Diamond Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 05, 2024

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St

Nov 05, 2024

Black Diamond's BDTX-1535 Shows 42% Response Rate in Lung Cancer Trial, Reports Q3 Results | BDTX Stock News - StockTitan

Nov 05, 2024

Nov 02, 2024

Black Diamond Group Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 02, 2024

Nov 01, 2024

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Nov 01, 2024

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short Interest - Defense World

Nov 01, 2024

Oct 31, 2024

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 5.9% in October - MarketBeat

Oct 31, 2024

Oct 26, 2024

Foundations Investment Advisors LLC Has $445,000 Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World

Oct 26, 2024

Oct 16, 2024